Remdesivir COVID 19 Market Analysis and Global Forecast 2023-2033
$ 1,390.00 – $ 5,520.00
Remdesivir (COVID 19) Market Research Report: Information By Dosage Type (5mg, 10 mg, 100mg), By Distribution Channel (Hospitals, Drug stores, Others), and by Region — Forecast till 2033
Page: 106
Remdesivir COVID 19 Market Overview
The Remdesivir COVID 19 Market Size is expected to reach USD 10.88 Billion by 2033. The Remdesivir COVID 19 Market industry size accounted for USD 6.36 Billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 40.22% from 2023 to 2033. The Remdesivir COVID-19 Market refers to the global marketplace for the antiviral drug Remdesivir, which is used for the treatment of COVID-19. This market encompasses various aspects, including the production, distribution, sales, and regulation of Remdesivir as a therapeutic option for COVID-19 patients.
The Remdesivir COVID-19 Market is a critical segment of the broader pharmaceutical market, especially in the context of ongoing global efforts to combat the COVID-19 pandemic. As the understanding of COVID-19 and its treatment options continues to advance, the market dynamics may shift, influenced by factors such as drug efficacy, regulatory approvals, and global health trends.
Global Remdesivir COVID 19 Market Synopsis
Remdesivir COVID 19 Market Dynamics
The major factors that have impacted the growth of Remdesivir COVID 19 Market are as follows:
Drivers:
Ø COVID-19 Pandemic
The ongoing spread of COVID-19, including waves of infections and the emergence of new variants, has driven demand for effective treatments like Remdesivir. The drug is often used for hospitalized patients with severe symptoms, leading to sustained demand. Public awareness of COVID-19 treatment options, along with healthcare policies that prioritize the availability of effective treatments, has contributed to the sustained demand for Remdesivir. Favorable pricing strategies and reimbursement policies by healthcare systems and insurance providers have made Remdesivir more accessible, driving its uptake in various regions.
Restraint:
- Perception of High Cost and Accessibility Issues and Development of Generic Versions
The high cost of Remdesivir can be a barrier, especially in low- and middle-income countries where healthcare resources are limited. This can lead to unequal access to the drug, limiting its market penetration in certain regions. The introduction of generic versions of Remdesivir in some regions, particularly in low-income countries, may lead to price competition and reduce the market share of the original branded product by Gilead Sciences.
Opportunity:
⮚ Generic Drug Production
Licensing agreements for the production of generic versions of Remdesivir can create opportunities for expanding market share, especially in regions where affordability is a concern. Generic production can also help meet demand in countries with limited healthcare budgets. Research and development into combination therapies, where Remdesivir is used alongside other antiviral drugs or treatments, can enhance its efficacy and broaden its application. This can lead to increased usage in various treatment protocols, even beyond COVID-19.
Remdesivir COVID 19 Market Segment Overview
By Dosage Type
Based on Dosage Type, the market is segmented based on 5mg, 10 mg and 100mg. the 100mg segment dominant the market. An increasing number of people in emerging nations are becoming overweight, and consumer awareness of low-calorie beverages is rising.
By Distribution Channel
Based on Distribution Channel, the market has been divided into Hospitals, Drug stores and Others. The hospitals segment dominant the market. The industry is expanding due to the prevalence of weight loss supplements in department stores, drug stores, health and beauty salons, and retail pharmacies. An organisation of people who operate in the construction sector is referred to as a “ecosystem”.
Global Remdesivir COVID 19 Market Regional Analysis
Based on region, the global Remdesivir COVID 19 Market has been divided into North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America. North America is projected to dominate the use of the Remdesivir COVID 19 Market followed by the Asia-Pacific and Europe regions.
Global Remdesivir COVID 19 North America Market
North America holds a dominant position in the Remdesivir COVID 19 Market. The U.S. is one of the largest markets for Remdesivir, primarily due to the high number of COVID-19 cases and hospitalizations. The FDA granted emergency use authorization (EUA) early in the pandemic, followed by full approval, making it a key treatment option. Government stockpiling and widespread healthcare coverage have also contributed to high demand.
Global Remdesivir COVID 19 Asia-Pacific Market
The Asia-Pacific region has indeed emerged as the fastest-growing market for the Remdesivir COVID 19 Market industry. China developed its own COVID-19 treatments, Remdesivir has been used in certain cases, particularly in severe infections. The market is relatively smaller compared to other regions due to China’s strict COVID-19 control measures and preference for domestic treatments and India represents a significant market, especially for generic versions of Remdesivir. High infection rates and hospitalization during COVID-19 waves have driven demand. Several Indian pharmaceutical companies produce and distribute generic Remdesivir, making it more accessible.
Competitive Landscape
The global Remdesivir COVID 19 Market is highly competitive, with numerous players offering a wide range of software solutions. The competitive landscape is characterized by the presence of established companies, as well as emerging startups and niche players. To increase their market position and attract a wide consumer base, the businesses are employing various strategies, such as product launches, and strategic alliances.
Prominent Players:
- Gilead Sciences, Inc.
- Mylan
- Cipla
- Hetero Labs
- Bright Gene
- Hainan Haiyao
- Kelun Pharma
- Hunan Warrant Pharmaceutical
- Borui Bio-Pharmaceutical
- Jubilant Life Sciences
Key Development
In April 2021, Remdesivir output at India’s Cipla Ltd (CIPL.NS) has been increased to assist satisfy “unprecedented demand” as the nation fights a major second wave of infections.
Scope of the Report
Global Remdesivir COVID 19 Market, by Dosage Type
- 5 mg
- 10 mg
- 100 mg
Global Remdesivir COVID 19 Market, by Distribution Channel
- Hospitals
- Drug stores
- Others
Global Remdesivir COVID 19 Market, by Region
- North America
- US
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Benelux
- Nordic
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- Indonesia
- Austalia
- Malaysia
- India
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of Middle East & Africa
| Parameters | Indicators |
|---|---|
| Market Size | 2033: $10.88 Billion |
| CAGR | 40.22% CAGR (2023-2033) |
| Base year | 2022 |
| Forecast Period | 2023-2033 |
| Historical Data | 2021 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Key Segmentations | Dosage Type, Distribution Channel |
| Geographies Covered | North America, Europe, Asia-Pacific, Latin America, Middle East, Africa |
| Key Vendors | Gilead Sciences, Inc., Mylan, Cipla, Hetero Labs, Bright Gene, Hainan Haiyao, Kelun Pharma, Hunan Warrant Pharmaceutical, Borui Bio-Pharmaceutical and Jubilant Life Sciences |
| Key Market Opportunities | • The growing demand for healthier food options • The rise of e-commerce and online food delivery platforms |
| Key Market Drivers | • Generic Drug Production |
REPORT CONTENT BRIEF:
- High-level analysis of the current and future Remdesivir COVID 19 Market trends and opportunities
- Detailed analysis of current market drivers, restraining factors, and opportunities in the future
- Remdesivir COVID 19 Market historical market size for the year 2021, and forecast from 2023 to 2033
- Remdesivir COVID 19 Market share analysis at each product level
- Competitor analysis with detailed insight into its product segment, Government & Defense strength, and strategies adopted.
- Identifies key strategies adopted including product launches and developments, mergers and acquisitions, joint ventures, collaborations, and partnerships as well as funding taken and investment done, among others.
- To identify and understand the various factors involved in the global Remdesivir COVID 19 Market affected by the pandemic
- To provide a detailed insight into the major companies operating in the market. The profiling will include the Government & Defense health of the company’s past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.
Press Release
Global Energy Trading Platform Market Forecast to Reach USD 10.98 Billion by 2034, Growing at a 14.28% CAGR
Global Critical Mineral Market Forecast to Reach USD 498.22 Billion by 2033, Growing at a 5.78% CAGR
Global Progressive Web Apps Market Forecast to Reach USD 25.56 Billion by 2034, Growing at an 8.65% CAGR
Global EV On-Board Battery Chargers Market Forecast to Reach USD 25.88 Billion by 2034, Growing at an 18.21% CAGR
Global Disposable Syringes Market Forecast to Reach USD 27.65 Billion by 2034, Growing at a 9.53% CAGR
Global Bituminous Paints Market Forecast to Reach USD 2.65 Billion by 2034, Growing at a 2.5% CAGR
Global Managed Services Market Forecast to Reach USD 847.21 Billion by 2034, Growing at a 7.14% CAGR
The Cosmetic Laser Market Is Estimated To Record a CAGR of Around 14.01% During The Forecast Period
Global Chloroprene Rubber Market Forecast to Reach USD 10.52 Billion by 2033, Growing at a 6.25% CAGR
The Cell Separation Market Is Estimated To Record a CAGR of Around 9.98% During The Forecast Period
Frequently Asked Questions (FAQ)
What is the growth rate of the global Remdesivir (COVID 19) Market?
The global Remdesivir (COVID 19) Market is growing at a CAGR of 40.22% over the next 10 years
Which region has the highest growth rate in the market of Remdesivir (COVID 19) Market?
Asia Pacific is expected to register the highest CAGR during 2023-2033
Which region has the largest share of the global Remdesivir (COVID 19) Market?
North America holds the largest share in 2022
Who are the key players in the global Remdesivir (COVID 19) Market?
Gilead Sciences, Inc., Mylan, Cipla, Hetero Labs, Bright Gene, Hainan Haiyao, Kelun Pharma, Hunan Warrant Pharmaceutical, Borui Bio-Pharmaceutical and Jubilant Life Sciences are the major companies operating in the market
Do you offer Post Sale Support?
Yes, we offer 16 hours of analyst support to solve the queries
Do you sell particular sections of a report?
Yes, we provide regional as well as country-level reports. Other than this we also provide a sectional report. Please get in contact with our sales representatives
Table of Content
Chapter 1. Executive Summary Chapter 2. Scope of The Study 2.1. Market Definition 2.2. Scope of The Study 2.2.1. Objectives of Report Chapter 3. Evolve BI Methodology Chapter 4. Market Insights and Trends 4.1. Supply/ Value Chain Analysis 4.2. Porter’s Five Forces Analysis 4.2.1. Threat of New Entrants 4.2.2. Bargaining Power of Buyers 4.2.3. Bargaining Power of Suppliers 4.2.4. Threat of Substitutes 4.2.5. Industry Rivalry 4.3. Impact of COVID-19 on Remdesivir (COVID 19) Market 4.3.1. Impact on Market Size 4.3.2. End User Trend, Preferences and Budget Impact 4.3.3. Regulatory Framework/Government Policies 4.3.4. Key Players Strategy to Tackle Negative Impact 4.3.5. Opportunity Window Chapter 5. Market Dynamics 5.1. Introduction 5.2. DRO Analysis 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities Chapter 6. Global Remdesivir (COVID 19) Market, By Dosage Type 6.1. Introduction 6.2. 5mg 6.3. 10 mg 6.4. 100mg Chapter 7. Global Remdesivir (COVID 19) Market, By Distribution Channel 7.1. Introduction 7.2. Hospitals 7.3. Drug stores 7.4. Others Chapter 8. Global Remdesivir (COVID 19) Market, By Region 8.1. Introduction 8.2. North America 8.2.1. Introduction 8.2.2. Driving Factors, Opportunity Analyzed and Key Trends 8.2.3. Market Size and Forecast, By Country, 2020 - 2028 8.2.4. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.2.5. Market Size and Forecast, By Distribution Channel, 2020 – 2026 8.2.6. US 8.2.6.1. Introduction 8.2.6.2. Driving Factors, Opportunity Analyzed and Key Trends 8.2.6.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.2.6.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.2.7. Canada 8.2.7.1. Introduction 8.2.7.2. Driving Factors, Opportunity Analyzed and Key Trends 8.2.7.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.2.7.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.3. Europe 8.3.1. Introduction 8.3.2. Driving Factors, Opportunity Analyzed and Key Trends 8.3.3. Market Size and Forecast, By Country, 2020 - 2028 8.3.4. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.3.5. Market Size and Forecast, By Distribution Channel, 2020 – 2026 8.3.6. Germany 8.3.6.1. Introduction 8.3.6.2. Driving Factors, Opportunity Analyzed and Key Trends 8.3.6.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.3.6.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.3.7. France 8.3.7.1. Introduction 8.3.7.2. Driving Factors, Opportunity Analyzed and Key Trends 8.3.7.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.3.7.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.3.8. UK 8.3.8.1. Introduction 8.3.8.2. Driving Factors, Opportunity Analyzed and Key Trends 8.3.8.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.3.8.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.3.9. Italy 8.3.9.1. Introduction 8.3.9.2. Driving Factors, Opportunity Analyzed and Key Trends 8.3.9.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.3.9.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.3.10. Rest of Europe 8.3.10.1. Introduction 8.3.10.2. Driving Factors, Opportunity Analyzed and Key Trends 8.3.10.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.3.10.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.4. Asia-Pacific 8.4.1. Introduction 8.4.2. Driving Factors, Opportunity Analyzed and Key Trends 8.4.3. Market Size and Forecast, By Country, 2020 - 2028 8.4.4. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.4.5. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.4.6. China 8.4.6.1. Introduction 8.4.6.2. Driving Factors, Opportunity Analyzed and Key Trends 8.4.6.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.4.6.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.4.7. India 8.4.7.1. Introduction 8.4.7.2. Driving Factors, Opportunity Analyzed and Key Trends 8.4.7.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.4.7.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.4.8. Japan 8.4.8.1. Introduction 8.4.8.2. Driving Factors, Opportunity Analyzed and Key Trends 8.4.8.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.4.8.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.4.9. South Korea 8.4.9.1. Introduction 8.4.9.2. Driving Factors, Opportunity Analyzed and Key Trends 8.4.9.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.4.9.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.4.10. Rest of Asia-Pacific 8.4.10.1. Introduction 8.4.10.2. Driving Factors, Opportunity Analyzed and Key Trends 8.4.10.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.4.10.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.5. Rest of The World (RoW) 8.5.1. Introduction 8.5.2. Driving Factors, Opportunity Analyzed and Key Trends 8.5.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.5.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.5.5. Market Size and Forecast, By Region, 2020 - 2028 8.5.6. South America 8.5.6.1. Introduction 8.5.6.2. Driving Factors, Opportunity Analyzed and Key Trends 8.5.6.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.5.6.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 8.5.7. Middle East and Africa 8.5.7.1. Introduction 8.5.7.2. Driving Factors, Opportunity Analyzed and Key Trends 8.5.7.3. Market Size and Forecast, By Dosage Type, 2020 - 2028 8.5.7.4. Market Size and Forecast, By Distribution Channel, 2020 - 2028 Chapter 9. Competitive Landscape 9.1. Introduction 9.2. Vendor Share Analysis, 2020/Key Players Positioning, 2020 Chapter 10. Company Profiles 10.1. Gilead Sciences, Inc. 10.1.1. Business Overview 10.1.2. Financial Analysis 10.1.3. Dosage Portfolio 10.1.4. Recent Development and Strategies Adopted 10.1.5. SWOT Analysis 10.2. Mylan 10.2.1. Business Overview 10.2.2. Financial Analysis 10.2.3. Dosage Portfolio 10.2.4. Recent Development and Strategies Adopted 10.2.5. SWOT Analysis 10.3. Cipla 10.3.1. Business Overview 10.3.2. Financial Analysis 10.3.3. Dosage Portfolio 10.3.4. Recent Development and Strategies Adopted 10.3.5. SWOT Analysis 10.4. Hetero Labs 10.4.1. Business Overview 10.4.2. Financial Analysis 10.4.3. Dosage Portfolio 10.4.4. Recent Development and Strategies Adopted 10.4.5. SWOT Analysis 10.5. Bright Gene 10.5.1. Business Overview 10.5.2. Financial Analysis 10.5.3. Dosage Portfolio 10.5.4. Recent Development and Strategies Adopted 10.5.5. SWOT Analysis 10.6. Hainan Haiyao 10.6.1. Business Overview 10.6.2. Financial Analysis 10.6.3. Dosage Portfolio 10.6.4. Recent Development and Strategies Adopted 10.6.5. SWOT Analysis 10.7. Kelun Pharma 10.7.1. Business Overview 10.7.2. Financial Analysis 10.7.3. Dosage Portfolio 10.7.4. Recent Development and Strategies Adopted 10.7.5. SWOT Analysis 10.8. Hunan Warrant Pharmaceutical 10.8.1. Business Overview 10.8.2. Financial Analysis 10.8.3. Dosage Portfolio 10.8.4. Recent Development and Strategies Adopted 10.8.5. SWOT Analysis 10.9. Borui Bio-Pharmaceutical 10.9.1. Business Overview 10.9.2. Financial Analysis 10.9.3. Dosage Portfolio 10.9.4. Recent Development and Strategies Adopted 10.9.5. SWOT Analysis 10.10. Jubilant Life Sciences 10.10.1. Business Overview 10.10.2. Financial Analysis 10.10.3. Dosage Portfolio 10.10.4. Recent Development and Strategies Adopted 10.10.5. SWOT Analysis Chapter 11. Key Takeaways
Connect to Analyst
Research Methodology
Our Most Viewed Report and gain instant expertise
Breast Cancer Liquid Biopsy Market Analysis and Global Forecast 2023-2033
Clinical Trial Management System Market Analysis and Global Forecast 2023-2033
Global Healthcare Blockchain Technology Market Analysis and Global Forecast 2023-2033
